Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have produced monoclonal antibodies (MoAb) to the Rb core and lipid A regions of Salmonella
lipopolysaccharide
(
LPS
) and have assessed their ability to inhibit
LPS
-mediated mitogenic responses in vitro, and to protect against
LPS
toxicity and lethal Salmonella infection in vivo. Monoclonal antibodies RC-8 and
RC-16
were specific for
LPS
Rb core determinants, and MoAb LA-1, LA-2, LA-3, LA-4 and LA-5 were specific for lipid A. Anti-lipid A MoAb LA-2, LA-3 and LA-5 were found to abrogate mitogenic responses of C3H/HeN spleen cells to smooth S. typhimurium
LPS
(S
LPS
) and to rough S. minnesota R595
LPS
(Re
LPS
). Monoclonal antibody LA-5 was effective in extending the median length of survival of C3H/HeN mice challenged with a lethal dose of either S
LPS
or Re
LPS
. Antibody LA-2 could extend the median length of survival of C3H/HeJ mice challenged with Re
LPS
but not with S
LPS
, and failed to extend significantly the length of survival of S
LPS
-challenged C3H/HeN and DBA/2 mice. Neither 20 micrograms of anti-Rb core or anti-lipid A MoAb nor 200 micrograms of anti-lipid A MoAb were able to protect C3H/HeN or BALB/c mice, respectively, against lethal infection with S. typhimurium SR-11. These results suggest that the importance of anti-lipid A antibodies in host defence may lie more in their ability to neutralize pathological effects of
LPS
, than in their ability to protect against bacterial infection.
...
PMID:Monoclonal antibodies to salmonella lipopolysaccharide: functional analysis of anti-lipid A antibodies. 329 50